

Table S1 Organ resections (n=90)

Resected organs	Number (%)
Kidney	17 (18.9)
Colon	29 (32.2)
Small intestine	7 (7.8)
Spleen	9 (10.0)
Stomach	4 (4.4)
Body and tail of the pancreas	5 (5.6)
Accessory	3 (3.3)
Omentum	2 (2.2)
Appendix	2 (2.2)
Adrenal gland	4 (4.4)
Uterus	1 (1.1)
Diaphragm	1 (1.1)
Ureter	1 (1.1)
Gallbladder	2 (2.2)
Refined	1 (1.1)
Duodenum	1 (1.1)
Bladder	1 (1.1)
Perirenal fat	1 (1.1)

Table S2 Univariate associations between clinicopathologic and treatment factors and survival types among patients with PR RPLPS

Variable	Analyses by survival type					
	OS			PFS		
	Median, mo	95% CI	P value	Median, mo	95% CI	P value
Age (years)			0.169			0.677
<60	67	43.15–68.16		30	27.37–50.22	
≥60	34	26.83–54.23		20	18.18–45.47	
Gender			0.304			0.378
Female	66	44.37–79.25		37.5	21.53–49.22	
Male	50	32.92–54.68		22	25.29–48.05	
Modus operandi			0.000*			0.009*
R0 resection	65	50.02–69.52		53	36.77–58.06	
R1 resection	19	13.53–56.14		12	7.18–38.0	
R2 resection	8	1.24–20.09		8	1.24–20.09	
Subtype			0.531			0.898
Well-differentiated	78	53.82–101.83		48	26.10–55.02	
Dedifferentiated	61	42.47–80.31		45	24.98–61.07	
Myxoid	56	30.15–68.30		14	11.43–52.58	
Pleomorphic	31	9.88–51.72		14	4.13–45.87	
Mixed	41	14.23–68.77		12	10.56–68.443	
Blood loss (mL)			0.006*			0.008*
<1,500	61	45.31–65.08		46.5	30.65–50.08	
≥1,500	9.5	7.97–55.24		9.5	3.82–38.78	
FNCLCC			0.000*			0.022*
1	70	58.23–80.93		55	37.17–61.57	
2	66	34.42–75.38		36	14.73–60.07	
3	20	13.28–37.54		12	8.51–33.14	
Tumor size (cm)			0.749			0.823
<20	60	37.72–66.91		27	24.24–48.67	
≥20	57	35.21–60.79		22.5	23.20–48.80	
No. of organs resected			0.122			0.089
<2	62	41.40–63.12		30	28.78–49.22	
2 or more	45	22.53–63.66		14	11.16–43.57	

*, significant. FNCLCC, French Federation of Cancer Centers Sarcoma Group; OS, overall survival; PFS, progression-free survival; R0 resection, complete resection + clean microscopic margins; R1 resection, complete resection + positive microscopic margins; R2 resection, macroscopically incomplete resection.

Table S3 Univariate associations between clinicopathologic and treatment factors and survival types among patients with LR RPLPS

Variable	Analyses by survival type					
	OS			PFS		
	Median, mo	95% CI	P value	Median, mo	95% CI	P value
Age (years)			0.575			0.563
<60	18	19.20–39.44		11	12.34–30.31	
≥60	20	5.63–52.37		10	3.49–33.11	
Gender			0.416			0.566
Female	23	18.74–46.79		12	8.73–27.65	
Male	12	13.71–38.37		9	10.88–34.86	
Modus operandi			0.000*			0.001*
R0 resection	61	38.32–72.61		26	20.44–53.29	
R1 resection	16.5	11.23–30.43		9	5.68–24.88	
R2 resection	4	1.60–12.95		4	1.60–12.95	
Subtype			0.960			0.929
Well-differentiated	18	16.79–46.86		12	6.21–17.79	
Dedifferentiated	12	15.85–55.07		8	3.07–12.93	
Myxoid	12	3.89–72.40		12	0.00–32.53	
Pleomorphic	19	10.10–47.40		10	7.06–12.94	
Mixed	22	9.17–26.16		9	4.20–13.80	
Blood loss (mL)			0.094			0.368
<1,500	25	22.23–48.77		12	13.31–34.53	
≥1,500	12	9.70–33.80		9	5.59–27.81	
FNCLCC			0.001*			0.005*
1	72	42.55–94.95		60	25.56–79.44	
2	23	9.00–45.40		12	5.58–18.43	
3	12	10.31–25.46		8.5	7.00–21.30	
Tumor size (cm)			0.024*			0.077
<20	30	25.27–51.97		12	13.03–38.21	
≥20	9	8.80–32.59		9	7.11–25.07	
No. of organs resected			0.644			0.774
<2	18	19.02–44.98		12	12.09–33.17	
2 or more	19	12.78–36.98		10	6.68–28.27	

*, significant. FNCLCC, French Federation of Cancer Centers Sarcoma Group; OS, overall survival; PFS, progression-free survival; R0 resection, Complete resection + clean microscopic margins; R1 resection, Complete resection + positive microscopic margins; R2 resection, macroscopically incomplete resection.